>"This has nothing to do with regulations and everything to do with how much money the companies are willing to throw at the problem."
Regulations are the cause of the costs; I am not saying that regulatory compliance is a waste of money, but it definitely is a cost which should be considered.
Delays also cost money and reduce return on investment (ROI), so I am sure the pharmaceutical companies do spend a great deal of money to expedite the process. Could all drug approvals go through faster if the pharma companies were willing to run larger trials? Would the FDA allow for these larger trials, and expedite the process for approval? What about rarer diseases, are they worth curing or treating on a timely basis?
Regulations are the cause of the costs; I am not saying that regulatory compliance is a waste of money, but it definitely is a cost which should be considered.
Delays also cost money and reduce return on investment (ROI), so I am sure the pharmaceutical companies do spend a great deal of money to expedite the process. Could all drug approvals go through faster if the pharma companies were willing to run larger trials? Would the FDA allow for these larger trials, and expedite the process for approval? What about rarer diseases, are they worth curing or treating on a timely basis?